JP2018516545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516545A5 JP2018516545A5 JP2017554886A JP2017554886A JP2018516545A5 JP 2018516545 A5 JP2018516545 A5 JP 2018516545A5 JP 2017554886 A JP2017554886 A JP 2017554886A JP 2017554886 A JP2017554886 A JP 2017554886A JP 2018516545 A5 JP2018516545 A5 JP 2018516545A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sarna
- composition according
- seq
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 52
- 108091029810 SaRNA Proteins 0.000 claims 35
- 229940078677 sarna Drugs 0.000 claims 35
- 238000000034 method Methods 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 108091081021 Sense strand Proteins 0.000 claims 8
- 230000000692 anti-sense effect Effects 0.000 claims 7
- 239000002502 liposome Substances 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 7
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 6
- 230000014509 gene expression Effects 0.000 claims 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 210000004185 liver Anatomy 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 2
- 108010082126 Alanine transaminase Proteins 0.000 claims 2
- 108010033918 Alanine-glyoxylate transaminase Proteins 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 claims 2
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims 2
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical group [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 102100026842 Serine-pyruvate aminotransferase Human genes 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000002577 cryoprotective agent Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 231100000835 liver failure Toxicity 0.000 claims 2
- 208000007903 liver failure Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 108010060800 serine-pyruvate aminotransferase Proteins 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 102300052097 Hepatocyte nuclear factor 4-alpha isoform HNF4-Alpha-2 Human genes 0.000 claims 1
- 101600072310 Homo sapiens Hepatocyte nuclear factor 4-alpha (isoform HNF4-Alpha-2) Proteins 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102100027378 Prothrombin Human genes 0.000 claims 1
- 108010094028 Prothrombin Proteins 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 1
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229940039716 prothrombin Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020158141A JP6931733B2 (ja) | 2015-04-22 | 2020-09-23 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150889P | 2015-04-22 | 2015-04-22 | |
| US62/150,889 | 2015-04-22 | ||
| US201562235778P | 2015-10-01 | 2015-10-01 | |
| US62/235,778 | 2015-10-01 | ||
| US201662308521P | 2016-03-15 | 2016-03-15 | |
| US62/308,521 | 2016-03-15 | ||
| PCT/GB2016/051117 WO2016170349A1 (en) | 2015-04-22 | 2016-04-21 | C/ebp alpha sarna compositions and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020158141A Division JP6931733B2 (ja) | 2015-04-22 | 2020-09-23 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516545A JP2018516545A (ja) | 2018-06-28 |
| JP2018516545A5 true JP2018516545A5 (enExample) | 2019-03-28 |
| JP6768701B2 JP6768701B2 (ja) | 2020-10-14 |
Family
ID=55948895
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554886A Active JP6768701B2 (ja) | 2015-04-22 | 2016-04-21 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2020158141A Active JP6931733B2 (ja) | 2015-04-22 | 2020-09-23 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2021132267A Pending JP2021192616A (ja) | 2015-04-22 | 2021-08-16 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2024038710A Pending JP2024079713A (ja) | 2015-04-22 | 2024-03-13 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020158141A Active JP6931733B2 (ja) | 2015-04-22 | 2020-09-23 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2021132267A Pending JP2021192616A (ja) | 2015-04-22 | 2021-08-16 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2024038710A Pending JP2024079713A (ja) | 2015-04-22 | 2024-03-13 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10912790B2 (enExample) |
| EP (1) | EP3286316A1 (enExample) |
| JP (4) | JP6768701B2 (enExample) |
| KR (2) | KR102599712B1 (enExample) |
| CN (2) | CN114525279A (enExample) |
| AU (3) | AU2016251415B9 (enExample) |
| SG (1) | SG11201707683YA (enExample) |
| WO (1) | WO2016170349A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102507624B1 (ko) * | 2013-11-22 | 2023-03-09 | 미나 테라퓨틱스 리미티드 | Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법 |
| JP2020501545A (ja) * | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのｒｎａ |
| EP4219715A3 (en) * | 2017-09-08 | 2023-09-06 | MiNA Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
| EP4183882A1 (en) | 2017-09-08 | 2023-05-24 | MiNA Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
| CN108103108A (zh) * | 2018-01-30 | 2018-06-01 | 上海交通大学医学院附属瑞金医院 | Cebpa基因缺失斑马鱼突变体的制备及其应用 |
| WO2019158720A1 (en) | 2018-02-16 | 2019-08-22 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
| CN110959042B (zh) * | 2018-04-10 | 2022-10-18 | 中美瑞康核酸技术(南通)研究院有限公司 | 一种新型小激活rna |
| CN112543809A (zh) * | 2018-06-15 | 2021-03-23 | 米纳治疗有限公司 | 包含C/EBPα saRNA的组合疗法 |
| EP4003423A4 (en) * | 2019-07-26 | 2024-03-06 | MiNA Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| EP4003060A4 (en) * | 2019-07-29 | 2023-08-02 | Brightseed, Inc. | Method for improving digestive health |
| AU2020349991A1 (en) * | 2019-09-20 | 2022-04-07 | Ractigen Therapeutics | Nucleic acid molecule for treating immune thrombocytopenia and application thereof |
| EP4069848A4 (en) * | 2019-12-03 | 2024-02-28 | Merck Sharp & Dohme LLC | IN VITRO CELL-BASED POWER DOSING |
| KR20230041707A (ko) * | 2020-07-17 | 2023-03-24 | 제론 코포레이션 | 피하 텔로머라제 억제제 조성물 및 이의 사용 방법 |
| GB202019692D0 (en) * | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
| EP4267182A4 (en) * | 2020-12-28 | 2025-01-08 | Douglas T. Gjerde | Temperature stable nucleic acid method for preparing vaccine |
| JP2024506882A (ja) * | 2021-02-07 | 2024-02-15 | ラクティゲン セラピューティクス | 化学修飾された低分子活性化ｒｎａ |
| EP4329777A1 (en) | 2021-04-28 | 2024-03-06 | MiNA Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| KR102428121B1 (ko) * | 2021-10-20 | 2022-08-08 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료를 위한 딜리버리 시스템 |
| US12523658B2 (en) * | 2021-08-27 | 2026-01-13 | The Board Of Regents Of The University Of Texas System | Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications |
| CN114306367B (zh) * | 2021-08-27 | 2023-03-28 | 赵小洋 | 一种含有C/EBPα-saRNA的组合物 |
| US20240207204A1 (en) * | 2022-12-12 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists |
| WO2024134199A1 (en) * | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2024165876A2 (en) * | 2023-02-10 | 2024-08-15 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| WO2024175887A1 (en) | 2023-02-22 | 2024-08-29 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| KR20240138691A (ko) * | 2023-03-13 | 2024-09-20 | 부산대학교 산학협력단 | 류마티스 관절염 진단용 바이오마커 조성물, 이를 이용한 진단용 키트 및 이를 이용한 류마티스 관절염 진단방법 |
| AU2024309737A1 (en) * | 2023-06-29 | 2026-01-08 | Repertoire Immune Medicines, Inc. | Lipid particles for delivering a payload |
| WO2025052098A1 (en) | 2023-09-08 | 2025-03-13 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| CN118480552B (zh) * | 2024-01-18 | 2024-10-01 | 成都先衍生物技术有限公司 | 一种靶向CEBPA基因表达的saRNA及其用途 |
| WO2025224036A1 (en) * | 2024-04-22 | 2025-10-30 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2026027887A2 (en) | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| CA2743074A1 (en) | 2008-11-13 | 2010-05-20 | Erasmus University Medical Center Rotterdam | Efficient detection of double mutants of the cebpa gene in aml. |
| JP6128846B2 (ja) * | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療 |
| GB201010557D0 (en) | 2010-06-23 | 2010-08-11 | Mina Therapeutics Ltd | RNA molecules and uses thereof |
| AU2011325956B2 (en) * | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| KR102039315B1 (ko) * | 2011-06-21 | 2019-11-04 | 미나 테라퓨틱스 리미티드 | 알부민 생산 및 세포 증식 |
| DE102011079572B4 (de) * | 2011-07-21 | 2024-12-05 | Endress+Hauser Conducta Gmbh+Co. Kg | Gradiometer zur Bestimmung der elektrischen Leitfähigkeit eines in einem Behältnis enthaltenen Mediums |
| CN104903450A (zh) * | 2012-11-05 | 2015-09-09 | 普隆奈治疗公司 | 寡核苷酸癌症疗法的给药和施用 |
| CA2890725A1 (en) * | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
| US20150299804A1 (en) * | 2012-11-15 | 2015-10-22 | Bristol-Myers Squibb Company | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent |
| KR102507624B1 (ko) * | 2013-11-22 | 2023-03-09 | 미나 테라퓨틱스 리미티드 | Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법 |
| JP7073109B2 (ja) * | 2015-07-02 | 2022-05-23 | シティ・オブ・ホープ | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
-
2016
- 2016-04-21 EP EP16721209.1A patent/EP3286316A1/en active Pending
- 2016-04-21 CN CN202210140475.5A patent/CN114525279A/zh active Pending
- 2016-04-21 KR KR1020177030397A patent/KR102599712B1/ko active Active
- 2016-04-21 AU AU2016251415A patent/AU2016251415B9/en active Active
- 2016-04-21 JP JP2017554886A patent/JP6768701B2/ja active Active
- 2016-04-21 WO PCT/GB2016/051117 patent/WO2016170349A1/en not_active Ceased
- 2016-04-21 CN CN201680034224.1A patent/CN108291228A/zh active Pending
- 2016-04-21 US US15/568,139 patent/US10912790B2/en active Active
- 2016-04-21 SG SG11201707683YA patent/SG11201707683YA/en unknown
- 2016-04-21 KR KR1020237037891A patent/KR102760315B1/ko active Active
-
2019
- 2019-07-31 AU AU2019210578A patent/AU2019210578B2/en active Active
-
2020
- 2020-09-23 JP JP2020158141A patent/JP6931733B2/ja active Active
- 2020-12-09 US US17/117,025 patent/US20210187007A1/en not_active Abandoned
-
2021
- 2021-08-16 JP JP2021132267A patent/JP2021192616A/ja active Pending
-
2022
- 2022-04-08 AU AU2022202355A patent/AU2022202355A1/en not_active Abandoned
-
2024
- 2024-03-13 JP JP2024038710A patent/JP2024079713A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516545A5 (enExample) | ||
| Wang et al. | Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance | |
| Lang et al. | Targeted co-delivery of the iron chelator deferoxamine and a HIF1α inhibitor impairs pancreatic tumor growth | |
| JP2021192616A5 (enExample) | ||
| ES2704986T3 (es) | Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab | |
| Hsu et al. | Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor | |
| Yang et al. | Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung caner | |
| Wang et al. | An engineered nanoplatform with tropism toward irradiated glioblastoma augments its radioimmunotherapy efficacy | |
| Zhou et al. | Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy | |
| JP2019519601A5 (enExample) | ||
| US11090330B2 (en) | Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same | |
| BR112020007476A2 (pt) | métodos para tratamento da infecção por hepatite b | |
| Du et al. | Multifunctional liposomes enable active targeting and twinfilin 1 silencing to reverse paclitaxel resistance in brain metastatic breast cancer | |
| Yuan et al. | Transforming cancer-associated fibroblast barrier into drug depots to boost chemo-immunotherapy in “shooting fish in a barrel” pattern | |
| JP2012067116A5 (enExample) | ||
| US20180071339A1 (en) | Combination of pharmaceutical preparations for tumor chemotherapy | |
| Shi et al. | Bacteria-driven tumor microenvironment-sensitive nanoparticles targeting hypoxic regions enhances the chemotherapy outcome of lung cancer | |
| Liu et al. | Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy | |
| JP2008540364A5 (enExample) | ||
| WO2023091960A1 (en) | Vectors for increasing nprl2 expression in cancer cells and methods of use thereof | |
| CN116600788B (zh) | 盐酸米托蒽醌脂质体的用途 | |
| Huang et al. | Protective effects of galnac-modified red blood cell-derived extracellular vesicles against liver diseases | |
| Gao et al. | PreS/2-21-guided siRNA nanoparticles target to inhibit hepatitis B virus infection and replication | |
| RU2018137058A (ru) | Композиция, включающая pic, для лечения рака | |
| Jin et al. | Docetaxel-loaded PEG-albumin nanoparticles with improved antitumor efficiency against non-small cell lung cancer |